On January 29, 2025, the U.S. Court of Appeals for the Federal Circuit affirmed the grant of a preliminary injunction by the Northern District of ...
Addressing a preliminary injunction in patent litigation related to the Biologics Price Competition and Innovation Act (BPCIA), the US Court ...
By reimbursing credit card fees, Regeneron subsidized the treatment costs, thereby gaining a competitive advantage over other anti-VEGF treatments. On this news, the price of Regeneron shares ...
Regeneron offered a price concession that lowered Eylea's selling price; (4) because retina practices were sensitive to higher prices when using credit cards to purchase anti-VEGF medications ...
The company revealed that those sales increased just 3% compared to the year earlier period, blaming "the lower net selling price compared to the third quarter of 2023" and "anti-VEGF category pricing ...
Securities Class Action Allegations Cast Shadow Over Regeneron Pharmaceuticals (REGN)– Hagens Berman
Regeneron offered a price concession that lowered EYLEA®’s selling price; (4) because retina practices were sensitive to higher prices when using a credit card to purchase anti-VEGF medications ...
Regeneron offered a price concession that lowered EYLEA’s selling price; (4) because retina practices were sensitive to higher prices when using a credit card to purchase anti-VEGF medications, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback